Published in Eur J Cancer on January 01, 1992
Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer (1996) 1.13
Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer (2000) 0.85
Cell Fate Decisions During Breast Cancer Development. J Dev Biol (2016) 0.75
Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol (1995) 0.75
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med (1998) 6.86
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med (1995) 3.88
Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology (1992) 2.75
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology (1995) 1.90
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol (2000) 1.82
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82
Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology (1994) 1.78
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Prognostic factors in breast cancer -- the formation of a prognostic index. Clin Oncol (1979) 1.74
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Cytological grading of breast carcinoma--a feasible proposition? Cytopathology (1990) 1.70
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 1.62
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer (1995) 1.60
Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer (2000) 1.58
Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer (1997) 1.56
Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. J Pathol (1987) 1.54
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 1.53
Season of initial detection in breast cancer. Br J Cancer (1991) 1.52
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett (2005) 1.50
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Subcutaneous mastectomy for primary operable breast cancer. Br J Surg (1984) 1.43
The role of the radiologist in breast diagnosis: a surgeon's personal view. Clin Radiol (1998) 1.43
The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br J Surg (1985) 1.42
Density of lymphocytic infiltration of primary breast cancer does not affect short-term disease-free interval or survival. J R Coll Surg Edinb (1990) 1.41
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat (2005) 1.41
Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med (2009) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol (1995) 1.39
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
Paget's disease of the nipple. Br J Surg (1991) 1.38
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol (1995) 1.34
A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer (1991) 1.32
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Results from a seven-year programme of breast self-examination in 89,010 women. Br J Cancer (1989) 1.31
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer (1986) 1.30
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ (1988) 1.29
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology (2003) 1.29
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) (1985) 1.29
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat (1994) 1.27
Diagnosis of breast cancer with core-biopsy and fine needle aspiration cytology. Aust N Z J Surg (1996) 1.26
Preoperative diagnosis in carcinoma of the breast. Br J Surg (1977) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol (1990) 1.25
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25